12 terminated. 12 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 12 | Terminated 12 |
| Phase 2 | 4 | Terminated 4 |
Follow Bendamustine: new trials by email Literature Review of Bendamustine trials Research Report on Bendamustine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Mesothelin-Specific T-Cells (FH-TCR-Tᴍsʟɴ) for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma Autologous Mesothelin-specific TCR-T Cells, Cyclophosphamide, Fludarabine - Metastatic Pancreatic Ductal Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8 | Phase 1 | Terminated | Fred Hutchinson Cancer Center | 9 | 2021-12-14 | 2026-07-02 |
| Isatuximab, Bendamustine, and Prednisone in Refractory Multiple Myeloma Isatuximab, Bendamustine, Prednisone - Multiple Myeloma | Phase 1 | Terminated | Washington University School of Medicine | 15 | 2020-04-03 | 2024-03-19 |
| FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies FT596, Cyclophosphamide, Fludarabine - Lymphoma, B-Cell, Chronic Lymphocytic Leukemia | Phase 1 | Terminated | Fate Therapeutics | 98 | 2020-03-19 | 2023-10-26 |
| FT516 in Subjects With Advanced Hematologic Malignancies FT516, Rituximab, Obinutuzumab - Acute Myelogenous Leukemia, B-cell Lymphoma | Phase 1 | Terminated | Fate Therapeutics | 72 | 2019-10-04 | 2023-10-26 |
| A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma TAK-659, Bendamustine, Rituximab - Lymphoma, Non-Hodgkin | Phase 1 | Terminated | Millennium Pharmaceuticals, Inc. | 43 | 2017-03-05 | 2022-02-18 |
| CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma 6,8-bis(benzylthio)octanoic acid, bendamustine hydrochloride, rituximab - B-cell Adult Acute Lymphoblastic Leukemia, B-cell Chronic Lymphocytic Leukemia | Phase 1 | Terminated | Wake Forest University Health Sciences | 1 | 2014-12-01 | 2018-07-02 |
| Carfilzomib With Bendamustine and Dexamethasone in Multiple Myeloma Bendamustine, Carfilzomib, Dexamethasone - Multiple Myeloma | Phase 1 / Phase 2 | Terminated | Suzanne Lentzsch, MD | 23 | 2013-11-01 | 2024-09-19 |
| Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma Bendamustine, Pentostatin, Ofatumumab - Chronic Lymphocytic Leukemia, B-Cell Non-Hodgkin's Lymphoma | Phase 1 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 10 | 2011-05-25 | 2025-04-29 |
| Bendamustine, Wkly Bortezomib, Lenalidomide and Dexamethasone for Multiple Myeloma Bendamustine - Multiple Myeloma | Phase 1 / Phase 2 | Terminated | Loyola University | 3 | 2011-05-05 | 2018-07-10 |
| Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma Bendamustine, Doxorubicin, Bortezomib - Multiple Myeloma | Phase 1 / Phase 2 | Terminated | Sherif Farag, MB, BS | 32 | 2010-07-01 | 2023-10-06 |
| Study Bendamustine Concurrent Whole Brain Radiation Brain Metastases From Solid Tumors Bendamustine - Brain Metastases | Phase 1 | Terminated | H. Lee Moffitt Cancer Center and Research Institute | 12 | 2009-04-01 | 2012-12-18 |
| Bendamustine in Acute Leukemia and MDS Bendamustine - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 27 | 2008-11-01 | 2012-12-04 |
Multiple Myeloma (4) · Leukemia (3) · Leukemia, Lymphocytic, Chronic, B-Cell (3) · Lymphoma (3) · Lymphoma, B-Cell (3) · Lymphoma, Non-Hodgkin (3) · Leukemia, Myeloid, Acute (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Brain Neoplasms (1) · Burkitt Lymphoma (1) · Intraocular Lymphoma (1) · Leukemia, Hairy Cell (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Follicular (1)
Fate Therapeutics (2) · Fred Hutchinson Cancer Center (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Loyola University (1) · M.D. Anderson Cancer Center (1) · Millennium Pharmaceuticals, Inc. (1) · Sherif Farag, MB, BS (1) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (1) · Suzanne Lentzsch, MD (1) · Wake Forest University Health Sciences (1) · Washington University School of Medicine (1)
United States (12) · Canada (1)
Edward Pan, M.D. (1) · Hagop M. Kantarjian, M.D. (1) · Jo Fili, MD (1) · Rachael Safyan, MD (1) · Ravi Vij, M.D. (1) · Scott Smith, MD, PhD (1) · Sherif Farag, M.B., B.S. (1) · Suzanne Lentzsch, MD (1) · Zanetta Lamar (1)
PMID 39227452, PMID 39798981, PMID 40610174
2016 (1), P30CA012197 (1)